Action PRTC PURETECH HEALTH PLC
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues PureTech Health plc

Actions

PRTC

GB00BY2Z0H74

Marché Fermé - London S.E.
Autres places de cotation
 17:35:12 25/04/2024 		Varia. 5j. Varia. 1 janv.
212,5 GBX 0,00 % Graphique intraday de PureTech Health plc +2,41 % +9,42 %
08:58 Le minier Anglo American examine l'offre d'achat de son rival BHP AN
08:44 Le minier Anglo American envisage un rachat par son rival BHP AN

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
PureTech Health : Proxy Form for 2024 AGM
PureTech Health : Notice of Meeting for 2024 AGM
PureTech Announces Annual Results for Year Ended December 31, 2023
PureTech touts "momentum" as grants shrivel but annual loss narrows
Miner Anglo American reviews takeover bid from rival BHP
Miner Anglo American eyes rival BHP takeover
Correction: Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY23 Loss $-0.24
Earnings Flash (PRTC.L) PURETECH HEALTH Reports FY23 Revenue $3.3M
Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY24 Loss $-0.24
PureTech Health plc Reports Earnings Results for the Full Year Ended December 31, 2023
PureTech Health plc - Notice of Results
PureTech Health: Notice of Results
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 in Idiopathic Pulmonary Fibrosis
EARNINGS AND TRADING: J Smart boosts revenue, Tertiary starts drilling
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
US FDA hands fast track to PureTech head and neck cancer treatment
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
Seaport Therapeutics Launches with $100 Million Oversubscribed Series a Financing Round to Advance Novel Neuropsychiatric Medicines
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PRTC
  4. Actualités PureTech Health plc
  5. Autres langues